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Purpose of review: describe why this review is timely and relevant. 
The cystic fibrosis lung has long been appreciated as a competitive niche for complex 
interactions between bacterial species.  The individual relationships between effects 
on the host, and thereafter clinical outcomes, has been poorly understood.  We aim to 
describe the role of Staphyloccus aureus, one of the most commonly encountered 
bacteria cultured from the respiratory tracts of people with CF, and it’s complex 
interplay with other organisms, with particular attention to Pseudomonas aeruginosa. 
 
Recent findings: describe the main themes in the literature covered by the 
article. 
We describe the challenges posed in understanding the role that S. aureus plays in 
the CF lung, including the difficulties in interpreting culture results depending upon 
sampling technique, relationships with P. aeruginosa and the rest of the microbiome, 
as well as discussing the relative merits and potential harms of antibiotic prophylaxis.  
Finally, we describe the particular challenge of methicillin-resistant S. aureus. 
 
Summary: describe the implications of the findings for clinical practice or 
research. 
We describe research underway that will address the long-held contentious issues of 
antibiotic prophylaxis. We also describe the emerging research interest in determining 
whether, at differences phases in the evolution of CF airways infection, S. aureus 
infection can have both harmful and protective effects for the host.   
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Shortly after cystic fibrosis (CF) was first described, by Dorothy Anderson, 
Staphylococcus aureus was recognised to be an important respiratory pathogen. 
Dorothy Anderson1 remarked that:  
 
“The bronchial secretion is viscous and may be abundant… Cultures taken early in 
the course of the disease grow Staph. aureus hemolyticus in nearly every case… A 
mixed flora is sometimes present in cases with a chronic bronchiectasis, with 
pyocyaneus as a common associate of the staphylococcus.” 
 
The term “pyocyaneus” was often used, at the time, to refer to Pseudomonas 
aeruginosa. Hence, since CF care was in its infancy, it has been recognised that S. 
aureus is a common pathogen, contributing to CF lung disease and that this 
organism is associated with P. aeruginosa infection. So, almost 70 years later, do 
these propositions still hold true and what are the practical implications for antibiotic 
treatment? The purpose of this article is to provide a critical review of literature 
published in the last few years, which describes the role of S. aureus and how the 
organism might interact with other players in the microbiological drama which unfolds 
in the CF airway. Earlier literature will also be cited, when relevant. 
 
What specimen to send for microbiological testing? 
In paediatric practice, many patients have minimal bronchiectasis and so do not 
produce sputum. Young children who do produce sputum may not expectorate it. In 
this age group, other approaches must be taken to obtain a respiratory specimen. 
The most commonly used is the oropharyngeal swab. Sometimes the child is asked 
to cough as the swab is taken (“cough swab”) in an attempt to improve the yield of 
true lower respiratory organisms. The diagnostic accuracy of oropharyngeal swabs 
has been compared with the “gold standard” of bronchoalveolar lavage (BAL). In a 
study which included 119 children under 18 months, with paired oropharyngeal and 
BAL samples2, Rosenfeld and colleagues found that the positive predictive value 
(PPV) of oropharyngeal swabs was poor for both S. aureus (64%) and P. aeruginosa 
(44%). The PPV is the likelihood of a positive oropharyngeal swab indicating true 
lower respiratory infection. The negative predictive value (the likelihood of a negative 
oropharyngeal swab indicating the absence of lower respiratory infection) was better 
- S. aureus (88%) and P. aeruginosa (95%). Similar negative predictive values have 
been found when the oropharyngeal sample has been collected using suction3*. A 
negative oropharyngeal sample may therefore help rule out significant lower 
respiratory infection.  
 
Bronchoscopy and BAL require a general anaesthetic, in most cases. Is there a way 
to improve diagnostic yield without having to resort to this procedure? A recent paper 
by Ronchetti et al 4** compared sputum induction in children (using nebulised 7% 
sodium chloride) with cough swab, single-lobe, two-lobe, and six-lobe BAL. They 
recruited 124 children (6 months - 18 years) and found sputum induction had a high 
technical success rate (84% of procedures yielded mucoid sputum) – though oral 
suction was usually required in the children under 6 years. The induced sputum 
sample was more likely to be pathogen positive than the cough swab, whether or not 
the child was symptomatic. Sputum induction was comparable to the 2 lobe BAL, 
with 69% of pathogens recovered from the induced sputum vs. 72% on two-lobe 
BAL. The results of induced sputum in young children are therefore promising, 
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although agreed standard operating procedures will be needed, if the technical 
success rates of the procedure are to be reproduced in other paediatric CF centres. 
 
What is normal flora? 
The historical reliance on oropharyngeal swabs, leads to difficulty in distinguishing 
between pathogens and normal upper airways flora in young children. One study 
found that, in healthy infants under 12 months, 27% of oropharyngeal cultures were 
positive for S. aureus vs. 28% in CF infants5. A U.S. study of healthy infants, having 
a routine procedure under sedation or anaesthesia, found S. aureus was found in 
oropharyngeal swabs from 48% of children6 and a study from the Netherlands found 
a rate of 36%7.  
 
In children with CF, the prevalence of S. aureus in the upper respiratory tract varies 
greatly with country of origin. In the US, the prevalence of S. aureus infection, on at 
least on occasion over 12 months, was 71% in 20158. In the UK, the figure is 30% 
(including both chronic and intermittent infection) for children and 35% for adults9. 
The disparity is even greater when these registry data are compared for methicillin 
resistant Staphylococcus aureus (MRSA) where the prevalence in the U.S. is 26%8 
vs. 2-3% in the U.K.9. The reasons for this disparity are unclear but acquisition of 
MRSA has been linked to a higher prevalence of MRSA in the patient’s CF Centre10* 
and to environmental factors such as air pollution, due to fine particulate matter11*. 
 
How does S. aureus interact with P. aeruginosa? 
Much recent work – both in the laboratory and in the clinic – has focused on S. 
aureus as part of an ensemble cast of other microorganisms. Of particular interest is 
the interaction between S. aureus and P. aeruginosa. This interaction appears to 
begin with conventional microbial competition. In a recent study of U.S. registry data, 
the presence of sensitive strains of S. aureus made subsequent P. aeruginosa 
infection less likely12*.  
 
However, there is evidence that competition may be followed by co-operation. A 
mouse model of chronic lung infection using bacteria embedded within agar beads, 
first infected mice with S. aureus and subsequently with P. aeruginosa 13. In this 
model, S. aureus was a pathogen in its own right and formed lung abscesses. 
However, S. aureus infection also made subsequent infection with P. aeruginosa 
more likely. P. aeruginosa may render S. aureus better able to survive in an 
environmental niche, such as the CF lung. A recent paper by Orazi and colleagues 
has shown that, when these organisms are grown in co-culture, P. aeruginosa 
promotes S. aureus resistance to vancomycin14*. The investigators propose that, 
when the organisms grow together, P. aeruginosa causes S. aureus to shift to 
fermentative growth this in turn leads to decreased susceptibility to antibiotics 
targeting the bacterial cell wall (such as vancomycin). However, the interaction is 
complex. P. aeruginosa isolates, from CF patients, can either reduce or enhance 
vancomycin killing of S. aureus15*. The same is true for tobramycin killing of S. 
aureus whereas most P. aeruginosa isolates will inhibit killing of S. aureus by 
ciprofloxacin. P. aeruginosa further aids and abets S. aureus by encouraging the 
formation of S. aureus small colony variants16*. These are phenotypic forms of S. 
aureus which are not detected using conventional culture techniques; are more 
antibiotic resistant; can sustain chronic infection and can survive intracellularly16*. 
However, a recent report has questioned the clinical importance of small colony 
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variants in children17. In a single centre where prophylaxis was used and where 
lower respiratory specimens were examined carefully for small colony variants – 
none were found. Finally, the production of alginate by the mucoid form of P. 
aeruginosa (characteristic of chronic infection in the CF airway) inhibits 
pseudomonas killing of S. aureus18.  
 
Laboratory studies suggest that, when S. aureus returns the favour by assisting P. 
aeruginosa, then S. aureus makes the ultimate sacrifice. P. aeruginosa, like many 
other pathogens, needs iron. The host’s innate immunity (e.g. lactoferrin) jealously 
guards the host’s iron stores. P. aeruginosa acquires iron by lysing S. aureus19. 
Furthermore, the DNA released by dead S. aureus contributes to the formation of a 
mixed-species biofilm comprising both P. aeruginosa and S. aureus20. This mixed-
species biofilm is also important in conferring resistance to aminoglycosides such as 
tobramycin21. 
 
What does the interaction between S. aureus and P. aeruginosa mean for 
those with CF?  
The implications of co-infection have been evaluated in a number of clinical studies. 
Patients with CF related diabetes (CFRD) are more likely to be coinfected with S. 
aureus and P. aeruginosa, than CF patients with normal glucose tolerance22. After 
adjustment for confounding, this dual infection was associated with decreased lung 
function and more frequent exacerbations of pulmonary symptoms. S. aureus small 
colony variants have been shown to be associated with a more rapid decline in lung 
function in children with CF, after adjusting for confounding variables23. In this clinical 
study, S. aureus small colony variants were associated with the use of trimethoprim-
sulphamethoxazole and with co-infection with P. aeruginosa. In contrast, a clinical 
study by Hubert et al (both children and adults) suggested that the annual decline in 
lung function was significantly higher for MRSA-P. aeruginosa co-infection only and 
not for co-infection with sensitive strains of S. aureus24. Single infection with S. 
aureus is seen in younger patients with better lung function25. 
 
S. aureus and the microbiota. 
More than a decade ago, culture independent methods of bacterial identification, 
such as 16S rDNA amplification, showed that a much greater number of 
microorganisms could be demonstrated in the CF lung than was possible with 
conventional culture. Of particular interest was the high prevalence of anaerobes 
(30%)26. However, the discovery of such a wide range of microorganisms in this 
environmental niche brought new problems. The use of 16S rDNA techniques simply 
demonstrates the presence of bacterial DNA, not viable organisms27 and organisms 
identified in sputum may have originated from the lower airway or indeed the oral 
cavity28. However, recent studies of the upper airway microbiota in young infants 
with CF, confirm the importance of S. aureus in this age group, in comparison to a 
group of non-CF infants29*. 
 
S. aureus: to treat of not to treat? 
This discussion of microbiological sampling, the significance (or otherwise) of 
positive bacterial isolates, interaction between S. aureus and P. aeruginosa (and its 
clinical implications) and the place of S. aureus amidst a wider microbiota serves to 
inform the discussion of when and whether to treat S. aureus. This will be considered 
under three headings: antistaphylococcal antibiotic prophylaxis; treatment of 
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sensitive strains of S. aureus ad hoc; and the treatment of respiratory infection with 
MRSA. Each of these categories will be considered in turn.  
 
Antistaphylococcal antibiotic prophylaxis 
The use of prophylactic antibiotics against S. aureus, from diagnosis by newborn 
screening until 3 years, is recommended in U.K. national guidelines30. In sharp 
contrast to this approach, guidelines in the U.S. recommend that antistaphylococcal 
antibiotic prophylaxis should not be used31. The AREST CF observational study has 
shown that isolation of S. aureus, de novo at 3 years, may predispose to 
bronchiectasis on chest CT and reduced FEF25-75, at school age32. It is of note, that 
no such effect was seen with de novo isolation of P. aeruginosa. Whilst this may 
provide some support for the U.K. approach, these observational data do not prove 
causation. A recent, registry based study33* has compared outcomes in the U.K. and 
the U.S. - where policies on the use of prophylaxis are very different. These data 
show that, in the first 3 years of life, initial acquisition of S. aureus and P. aeruginosa 
occurs significantly earlier, in the U.S. than in the U.K. A surprising finding of the 
same study came from a subgroup analysis of the U.K. data which showed that 
many U.K. children were not receiving flucloxacillin (the recommended first line 
prophylactic antibiotic). Furthermore, those who were prescribed flucloxacillin were 
more likely to acquire P. aeruginosa during the first 3 years (hazard ratio 2.53; 95% 
CI 1.71, 3.74, p<0.001) whereas there was no reduction in S. aureus. 
 
More robust conclusions regarding causation can be drawn from clinical trials. The 
Cochrane systematic review of clinical trials of antistaphylococcal antibiotic 
prophylaxis34* has recently been updated. The review includes 4 trials with 401 
randomised CF participants and shows that significantly fewer children randomised 
to prophylaxis had one or more isolate of S. aureus during the study period. There 
was no difference between arms in lung function, nutrition, hospital admissions, 
additional courses of antibiotics or adverse effects. In the first 3 years of data, there 
was a trend towards a lower cumulative isolation rate of P. aeruginosa in the 
prophylaxis group. However, there was a trend towards a higher rate from 4-6 years. 
A prospective, multicentre randomized clinical trial is currently in progress which 
compares continuous flucloxacillin and “as required” antibiotic therapy in infants 
identified by newborn screening is underway in the U.K. (ISRCTN18130649).  
 
Treatment of sensitive strains of S. aureus ad hoc 
Although treatment of sensitive strains of S. aureus with a 2 week course of oral 
antibiotics is recommended in guidelines30 and widely practiced, there is little 
evidence to support this. A retrospective review35 describes the response to ad hoc 
treatment of S. aureus in the lower respiratory tract in the Copenhagen CF Centre 
(where prophylaxis is not used). The study describes an annual rate of S. aureus 
infection of 47% in a population of 300 patients. Patients received between 2 and 6 
weeks of appropriate antibiotics. In 61% of cases the organism was eradicated on 
follow up (53% for the longer courses) and FEV1 improved significantly over baseline 
(by a median of 3.3%). 
 
In terms of chronic suppressive therapy for chronic infection with sensitive strains of 
S. aureus, a Cochrane review found no trials36. 
 
Treatment of respiratory infection with MRSA 
Formatted: Font: Italic
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There is an emerging consensus that MRSA is an important pathogen in CF rather 
than simply a marker of severe disease37*. A recent case control study from Brazil38 
has shown that patients infected with MRSA have a greater respiratory impairment at 
the time of chronic infection and disease progression is more rapid in patients with 
MRSA compared to those with sensitive strains of S. aureus. CF patients with MRSA 
have also been shown to have worse CT appearances than those who are free of 
infection39. This consensus has led to a randomised controlled trial of MRSA 
eradication in CF – STAR-too40*. This trial randomised participants to a regimen of 
observation only or oral trimethoprim-sulphamethoxazole for 2 weeks. (If allergic to 
sulphamethoxazole, minocycline plus oral rifampicin was given.) Drug treatment was 
combined with nasal, skin and environmental decontamination. The primary outcome 
(MRSA status at day 28) was significantly better in the active treatment group (82% 
negative) than in controls (26% negative). However, there was a substantial 
recurrence of MRSA infection in both groups during follow up. 
 
Conclusion 
S. aureus has much more than a bit part in the evolution of airways infection in 
young patients with CF. Initially, the organism competes with other pathogens to 
defend its environmental niche and there is historical and laboratory evidence that S. 
aureus can cause significant lung damage while it is the dominant pathogen. In 
many cases, this phase of competition ends with S. aureus the loser. This is followed 
by co-existence with a new dominant pathogen – often P. aeruginosa. Whether 
antibiotic therapy can play a major part in influencing this microbiological turf war, to 
favour the host with CF, will be determined in part by ongoing randomised controlled 
trials. 
 
 Respiratory sampling, and determining infection from normal flora, in young 
children with CF is challenging and poses difficulty to the treating clinician 
 Complex interactions between S. aureus and P. aeruginosa, resulting in 
differential outcomes for bacterial survival, have been observed in vivo 
 The relative merits and harms of approaches to early infection with S. aureus 
– prophylaxis or ad hoc, are being investigated in clinical trials 
 MRSA is a harmful pathogen in CF early eradication is possible but treating 
chronic infection poses more of a challenge 
 
Annotations 
[3]* This study showed that the diagnostic accuracy of oropharyngeal suction was 
similar to “oropharyngeal swabs” although the procedure can cause distress in 
younger children. 
[4]** The CF SPIT study demonstrated for the first time that a non-invasive technique 
(induced sputum with hypertonic saline) could achieve a similar diagnostic accuracy 
to bronchoscopy and lavage. 
[10]* An important registry study, looking at the antecedents of MRSA infection. It 
showed that many are not amenable to change (pancreatic insufficiency and CF 
related diabetes) though others (such as the prevalence of MRSA at a CF centre) 
may be.  
[11]* PM2.5 exposure was associated with a 68% increased risk of MRSA 
acquisition but not with an increased risk of acquiring sensitive strains of S. aureus, 
Achromobacter xylosoxidans or Stenotrophomonas maltophilia.  
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[12]* A large U.S. registry study which showed that P. aeruginosa infection was less 
likely to occur in patients first infected with S. aureus. 
[14]* A laboratory study showing that P. aeruginosa encourages S. aureus to adopt 
the fermentative mode of growth and confers upon S. aureus resistance to 
vancomycin. 
[15]* P. aeruginosa from CF and burn patients were cultured and supernatants 
added to S. aureus cultures to determine the effect on S. aureus resistance to 
vancomycin, ciprofloxacin and tobramycin.  
[16]* Comprehensive review of in vivo and in vitro interactions between P. 
aeruginosa and S. aureus. 
[29]* Meticulous study of the microbiota of CF and non-CF infants in the first 6 
months of life. 
[33]** Unique study of both U.S. and U.K. registry data showing earlier acquisition of 
S. aureus and P. aeruginosa in the U.S vs. the U.K. However flucloxacillin 
prophylaxis associated with earlier P. aeruginosa in the U.K.  
[34]** Benchmark systematic review showing that antistaphylococcal antibiotic 
prophylaxis leads to fewer children having one or more isolates of S. aureus. No 
difference in other clinical outcomes. 
[36]* Comprehensive review of risk factors for MRSA acquisition and treatment 
strategies.  
[39]* Landmark randomised controlled trial, showing the microbiological 
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